

FORM PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. P28506	Application No. 10/550,013
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Applicant Rudolf FAHRIG et al	
		Filing Date September 23, 2005	Group 1623

JUN 18 2008
U.S. PATENT & TRADEMARK OFFICE
RECEIVED
MAILED
SST

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

/M.C.H./	1	Fahrig et al., <i>RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients</i> , Anti-Cancer Drugs 2006, 17:1045-1056.
/M.C.H./	2	Fahrig et al., <i>Inhibition of Induced Chemoresistance by Cotreatment with (E)-5-(2-Bromovinyl)-2'-Deoxyuridine (RP101)</i> , Cancer Research 63, 5745-5753, September 15, 2003.
/M.C.H./	3	U.S. Patent Application 11/853,540, filed September 11, 2007.

EXAMINER /Michael Henry/ **DATE CONSIDERED** 09/14/2008
***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.